Mayne Pharma Group 過去の業績

過去基準チェック /06

Mayne Pharma Groupの収益は年間平均-0.9%の割合で減少していますが、 Pharmaceuticals業界の収益は年間増加しています。収益は年間13.1% 16.6%割合で減少しています。

主要情報

-0.9%

収益成長率

0.9%

EPS成長率

Pharmaceuticals 業界の成長	7.3%
収益成長率	-16.6%
株主資本利益率	-37.1%
ネット・マージン	-43.4%
前回の決算情報	30 Jun 2024

Recent updates

収支内訳

Mayne Pharma Group の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

DB:HG6 収益、費用、利益 ( )AUD Millions
日付	収益	収益	G+A経費	研究開発費
30 Jun 24	388	-169	243	20
31 Mar 24	354	-221	257	19
31 Dec 23	319	-274	272	18
30 Sep 23	251	-296	261	17
30 Jun 23	184	-317	251	16
31 Dec 22	59	-257	193	13
30 Sep 22	108	-233	187	12
30 Jun 22	157	-209	182	12
31 Mar 22	250	-151	184	15
31 Dec 21	342	-93	186	19
30 Sep 21	372	-151	179	20
30 Jun 21	401	-208	173	22
31 Mar 21	420	-232	180	22
31 Dec 20	439	-256	187	22
30 Sep 20	448	-174	194	24
30 Jun 20	457	-93	200	25
31 Mar 20	467	-196	210	26
31 Dec 19	478	-300	220	27
30 Sep 19	502	-290	231	28
30 Jun 19	525	-279	241	29
31 Mar 19	543	-118	230	27
31 Dec 18	561	43	219	25
30 Sep 18	546	-46	208	20
30 Jun 18	530	-134	197	15
31 Mar 18	526	-146	196	12
31 Dec 17	521	-158	194	8
30 Sep 17	547	-35	192	8
30 Jun 17	573	89	190	8
31 Mar 17	504	90	173	8
31 Dec 16	435	91	156	8
30 Sep 16	351	64	136	7
30 Jun 16	267	37	115	7
31 Mar 16	238	30	105	7
31 Dec 15	209	23	94	7
30 Sep 15	175	15	77	6
30 Jun 15	141	8	60	4
31 Mar 15	137	12	50	3
31 Dec 14	133	17	40	3
30 Sep 14	138	19	37	4
30 Jun 14	143	21	35	5
31 Mar 14	135	15	33	5
31 Dec 13	126	8	31	6

質の高い収益: HG6は現在利益が出ていません。

利益率の向上: HG6は現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: HG6は利益が出ておらず、過去 5 年間で損失は年間0.9%の割合で増加しています。

成長の加速: HG6の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: HG6は利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 28.7% ) と比較することは困難です。

株主資本利益率

高いROE: HG6は現在利益が出ていないため、自己資本利益率 ( -37.13% ) はマイナスです。

Mayne Pharma Group 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Full year 2024 earnings released: AU$2.12 loss per share (vs AU$3.86 loss in FY 2023)

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024

Full year 2023 earnings released: AU$3.86 loss per share (vs AU$3.20 loss in FY 2022)

Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Recent updates

Full year 2024 earnings released: AU$2.12 loss per share (vs AU$3.86 loss in FY 2023)

No longer forecast to breakeven

New minor risk - Profitability

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Forecast to breakeven in 2026

New minor risk - Share price stability

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024

High number of new directors

Mayne Pharma Group Limited Approves Election of Anne Lockwood

CEO, MD & Director recently bought €84k worth of stock

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: AU$3.86 loss per share (vs AU$3.20 loss in FY 2022)

New minor risk - Financial data availability

Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

First half 2023 earnings released: AU$0.078 loss per share (vs AU$0.62 loss in 1H 2022)

Mayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring

Inaugural dividend of AU$0.065 per share

Now 48% undervalued after recent price drop

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

High number of new directors

High number of new directors

Mayne Pharma Group Limited Declares Fully Franked Special Dividend, Payable on 27 January 2023

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Mayne Pharma Group Limited Announces Executive Changes Effective from 1 October 2022

Mayne Pharma Group Limited Announces Management Changes

Full year 2022 earnings released: AU$0.16 loss per share (vs AU$0.13 loss in FY 2021)

Scott Richards Plans to Retire as CEO of Mayne Pharma Group Limited

FDA Grants Approval to Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA of the Abbreviated New Drug Application (Anda) for Haloette

Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces NEXTSTELLIS Oral Contraceptive Now Available in Australia

Mayne Pharma Group Limited Announces CFO Changes

Forecast breakeven date pushed back to 2024

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Mayne Pharma Expands U.S Dermatology Portfolio

Insufficient new directors

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods Administration Approval of NEXTSTELLIS® Oral Contraceptive

High number of new directors

Independent Non Executive Director Bruce Mathieson has left the company

Independent Chairman Roger Corbett has left the company

Independent Chairman Roger Corbett has left the company

U.S. Food and Drug Administration Approves Mayne Pharma LEXETTE for Adolescent Plaque Psoriasis

Forecast to breakeven in 2023

Independent Non-Executive Director recently bought €85k worth of stock

Full year 2021 earnings released: AU$0.13 loss per share (vs AU$0.061 loss in FY 2020)

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Nextstellis Receives FDA Marketing Exclusivity and Phase Iii Data Published

Mayne Pharma Announces New Data Showing Treatment with Nextstellis® Investigational Combined Oral Contraceptive (Coc) Containing Drospirenone (Drsp) and Estetrol

Mayne Pharma Group Limited Launches Another Generic Oral Contraceptive

First half 2021 earnings released: AU$0.12 loss per share (vs AU$0.012 loss in 1H 2020)

Revenue beats expectations

Mayne Pharma Group Limited to Report Fiscal Year 2021 Results on Aug 27, 2021

Mayne Pharma Group Limited Launches MICROGESTIN 24 FE Tablets in the United States

New 90-day high: €0.24

Mayne Pharma Group Limited Provides Update on Women's Health Pipeline

Mayne Pharma Group Limited Appoints Peter Paltoglou as Chief Financial Officer

Full year earnings released

Mayne Pharma Group Limited to Report Fiscal Year 2020 Results on Aug 21, 2020

Mayne Pharma Group Limited(ASX:MYX) dropped from S&P/ASX 200 Index

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06